← 產業報告目錄
South Africa Substance Abuse Treatment Market by Treatment Research Report by Type (Alcohol Addiction Treatment, Drug Abuse Treatment, and Tobacco/Nicotine Addiction Treatment), Route of Administration (Oral and Intravenous Treatment), by End User (Hospitals & Clinics, Private Rehabilitation Treatment Centres and Others) Forecast to 2032
授權報價
| Single User Price | $2,950 USD |
| Multi User Licence (up to 10 users) | $3,950 USD |
| Enterprisewide Price (Global Site License) | $5,250 USD |
報告摘要
South Africa Substance Abuse Treatment Market by Treatment Research Report by Type (Alcohol Addiction Treatment, Drug Abuse Treatment, and Tobacco/Nicotine Addiction Treatment), Route of Administration (Oral and Intravenous Treatment), by End User (Hospitals & Clinics, Private Rehabilitation Treatment Centres and Others) Forecast to 2032
Overview of the Market
Over the course of the review year, the South African substance abuse treatment market is anticipated to grow at a noteworthy CAGR of 8.78%. Depending on the needs of the patient, common therapy approaches include medication-assisted treatment (MAT), counseling, detoxification, and rehabilitation programs.
The market for substance addiction treatment in South Africa is being driven by rising drug and alcohol usage as well as funding for treatment initiatives. The community's stigma and discrimination, as well as market participants' voluntary product recalls, are further impeding the expansion of the South African drug addiction treatment industry. However, the market will have future development prospects because to government assistance, programs, public awareness, and education.
Segmentation of the Market
The market for substance abuse treatment in South Africa has been divided into three segments based on the type of treatment: drug abuse treatment, alcohol addiction treatment, and tobacco/nicotine addiction treatment.
The market has been divided into two segments based on the route of administration: oral and intravenous treatment.
The South African market for substance addiction treatment has been divided into three segments based on the end user: private rehabilitation treatment centers, hospitals and clinics, and others.
Key Players
Teva Pharmaceutical Industries Ltd., GSK Plc, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Mallinckrodt PLC, and Adcock Ingram are the major participants in the South African drug misuse treatment market.
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ............................................................................................................... 13
2 MARKET INTRODUCTION ............................................................................................................ 15
2.1 DEFINITION .................................................................................................................................................................. 15
2.2 SCOPE OF THE STUDY .............................................................................................................................................. 15
2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 15
2.4 MARKET STRUCTURE .............................................................................................................................................. 15
3 RESEARCH METHODOLOGY ...................................................................................................... 16
3.1 OVERVIEW .................................................................................................................................................................... 16
3.2 DATA FLOW .................................................................................................................................................................. 18
3.2.1 DATA MINING PROCESS ................................................................................................................................. 18
3.3 PURCHASED DATABASE: ......................................................................................................................................... 19
3.4 SECONDARY SOURCES: ............................................................................................................................................ 20
3.4.1 SECONDARY RESEARCH DATA FLOW: ............................................................................................................. 21
3.5 PRIMARY RESEARCH: ............................................................................................................................................... 22
3.5.1 PRIMARY RESEARCH DATA FLOW: ................................................................................................................. 23
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................................... 24
3.6.1 REVENUE ANALYSIS APPROACH ..................................................................................................................... 24
3.7 DATA FORECASTING................................................................................................................................................. 25
3.7.1 DATA FORECASTING TYPE .............................................................................................................................. 25
3.8 DATA MODELING ........................................................................................................................................................ 26
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............................................................................................................ 26
3.8.2 DATA MODELING: ........................................................................................................................................... 27
3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 29
4 MARKET DYNAMICS .................................................................................................................... 31
4.1 INTRODUCTION ........................................................................................................................................................... 31
4.2 DRIVERS ......................................................................................................................................................................... 32
4.2.1 INCREASING DRUG AND ALCOHOL CONSUMPTION .......................................................................................... 32
4.2.2 FUNDING FOR TREATMENT PROGRAMS .......................................................................................................... 32
4.3 RESTRAINTS ................................................................................................................................................................ 33
4.3.1 STIGMA AND DISCRIMINATION IN THE COMMUNITY ....................................................................................... 33
4.3.2 LACK OF PERCEIVED TREATMENT EFFICACY ................................................................................................... 33
4.4 OPPORTUNITY ............................................................................................................................................................. 34
4.4.1 GOVERNMENT SUPPORT AND INITIATIVES ...................................................................................................... 34
4.4.2 PUBLIC AWARENESS AND EDUCATION ............................................................................................................ 35
5 MARKET FACTOR ANALYSIS ...................................................................................................... 36
5.1 PORTER'S FIVE FORCES MODEL ........................................................................................................................... 36
5.1.1 THREAT OF NEW ENTRANTS ........................................................................................................................... 36
5.1.2 BARGAINING POWER OF SUPPLIERS ............................................................................................................... 37
5.1.3 THREAT OF SUBSTITUTES .............................................................................................................................. 37
5.1.4 BARGAINING POWER OF BUYERS .................................................................................................................... 37
5.1.5 INTENSITY OF RIVALRY .................................................................................................................................. 37
5.2 IMPACT OF COVID-19 ON SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET ................ 37
5.3 ESTIMATED MARKET SIZE FOR KWAZULU-NATAL (USD MILLION) ..................................................... 38
5.4 MARKET TRENDS IN KWAZULU-NATAL.......................................................................................................... 38
5.5 COMPARISON OF MAJOR DRUG AND ALCOHOL REHABILITATION FACILITIES IN SOUTH AFRICA
41
5.6 COMPARISON OF MAJOR DRUG AND ALCOHOL REHABILITATION FACILITIES IN KWAZULU-NATAL
42
5.7 QUALITATIVE OVERVIEW OF KWAZULU NATAL MIDLANDS AS A LOCATION FOR DRUG AND
ALCOHOL TREATMENT FACILITIES ............................................................................................................................... 42
6 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, BY TREATMENT TYPE ........... 45
6.1 OVERVIEW .................................................................................................................................................................... 45
7 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
49
7.1 OVERVIEW .................................................................................................................................................................... 49
8 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, BY END USER ......................... 52
8.1 OVERVIEW .................................................................................................................................................................... 52
9 COMPETITIVE LANDSCAPE ........................................................................................................ 55
9.1 INTRODUCTION ........................................................................................................................................................... 55
9.2 MARKET SHARE ANALYSIS, 2023 ....................................................................................................................... 55
9.3 COMPETITOR DASHBOARD..................................................................................................................................... 56
9.4 PUBLIC PLAYERS STOCK SUMMARY ................................................................................................................. 57
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL .............................................................................. 57
10 COMPANY PROFILES .................................................................................................................. 58
10.1 GSK PLC .......................................................................................................................................................................... 58
10.1.1 COMPANY OVERVIEW ..................................................................................................................................... 58
10.1.2 FINANCIAL OVERVIEW .................................................................................................................................... 59
10.1.3 PRODUCT OFFERED ........................................................................................................................................ 59
10.1.4 KEY DEVELOPMENTS ...................................................................................................................................... 59
10.1.5 SWOT ANALYSIS ............................................................................................................................................ 60
10.1.6 KEY STRATEGIES ............................................................................................................................................ 60
10.2 TEVA PHARMACEUTICAL INDUSTRIES LTD. .................................................................................................. 61
10.2.1 COMPANY OVERVIEW ..................................................................................................................................... 61
10.2.2 FINANCIAL OVERVIEW .................................................................................................................................... 62
10.2.3 PRODUCTS OFFERED ...................................................................................................................................... 62
10.2.4 KEY DEVELOPMENTS ...................................................................................................................................... 63
10.2.5 SWOT ANALYSIS ............................................................................................................................................ 63
10.2.6 KEY STRATEGIES ............................................................................................................................................ 63
10.3 WELLONA PHARMA .................................................................................................................................................. 64
10.3.1 COMPANY OVERVIEW ..................................................................................................................................... 64
10.3.2 FINANCIAL OVERVIEW .................................................................................................................................... 64
10.3.3 PRODUCTS OFFERED ...................................................................................................................................... 65
10.3.4 KEY DEVELOPMENTS ...................................................................................................................................... 65
10.3.5 KEY STRATEGIES ............................................................................................................................................ 65
10.4 INTAS PHARMACEUTICALS LTD. ........................................................................................................................ 66
10.4.1 COMPANY OVERVIEW ..................................................................................................................................... 66
10.4.2 FINANCIAL OVERVIEW .................................................................................................................................... 66
10.4.3 PRODUCTS OFFERED ...................................................................................................................................... 67
10.4.4 KEY DEVELOPMENTS ...................................................................................................................................... 67
10.4.5 KEY STRATEGIES ............................................................................................................................................ 67
10.5 ROSEMONT PHARMACEUTICALS LIMITED ..................................................................................................... 68
10.5.1 COMPANY OVERVIEW ..................................................................................................................................... 68
10.5.2 FINANCIAL OVERVIEW .................................................................................................................................... 68
10.5.3 PRODUCTS OFFERED ...................................................................................................................................... 69
10.5.4 KEY DEVELOPMENTS ...................................................................................................................................... 69
10.5.5 KEY STRATEGIES ............................................................................................................................................ 69
10.6 MALLINCKRODT PLC ................................................................................................................................................ 70
10.6.1 COMPANY OVERVIEW ..................................................................................................................................... 70
10.6.2 FINANCIAL OVERVIEW .................................................................................................................................... 71
10.6.3 PRODUCTS OFFERED ...................................................................................................................................... 72
10.6.4 KEY DEVELOPMENTS ...................................................................................................................................... 72
10.6.5 SWOT ANALYSIS ............................................................................................................................................ 73
10.6.6 KEY STRATEGIES ............................................................................................................................................ 73
10.7 ADCOCK INGRAM ....................................................................................................................................................... 74
10.7.1 COMPANY OVERVIEW ..................................................................................................................................... 74
10.7.2 FINANCIAL OVERVIEW .................................................................................................................................... 75
10.7.3 PRODUCTS OFFERED ...................................................................................................................................... 75
10.7.4 KEY DEVELOPMENTS ...................................................................................................................................... 75
10.7.5 KEY STRATEGIES ............................................................................................................................................ 76
10.8 PFIZER INC. ................................................................................................................................................................... 77
10.8.1 COMPANY OVERVIEW ..................................................................................................................................... 77
10.8.2 FINANCIAL OVERVIEW .................................................................................................................................... 78
10.8.3 PRODUCTS OFFERED ...................................................................................................................................... 79
10.8.4 KEY DEVELOPMENTS ...................................................................................................................................... 79
10.8.5 SWOT ANALYSIS ............................................................................................................................................ 79
10.8.6 KEY STRATEGIES ............................................................................................................................................ 79
10.9 SUN PHARMACEUTICAL INDUSTRIES LTD. ..................................................................................................... 81
10.9.1 COMPANY OVERVIEW ..................................................................................................................................... 81
10.9.2 FINANCIAL OVERVIEW .................................................................................................................................... 82
10.9.3 PRODUCTS OFFERED ...................................................................................................................................... 83
10.9.4 KEY DEVELOPMENTS ...................................................................................................................................... 83
10.9.5 SWOT ANALYSIS ............................................................................................................................................ 83
10.9.6 KEY STRATEGIES ............................................................................................................................................ 83
10.10 UMSEBE HEALTHCARE ........................................................................................................................................... 85
10.10.1 COMPANY OVERVIEW ..................................................................................................................................... 85
10.10.2 FINANCIAL OVERVIEW .................................................................................................................................... 86
10.10.3 PRODUCTS OFFERED ...................................................................................................................................... 86
10.10.4 KEY DEVELOPMENTS ...................................................................................................................................... 86
10.10.5 KEY STRATEGIES ............................................................................................................................................ 86
11 DATA CITATIONS ......................................................................................................................... 87
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 27
TABLE 2 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, BY TREATMENT TYPE, 2019–2032 (USD MILLION) 46
TABLE 3 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, FOR ALCOHOL ADDICTION TREATMENT, BY TYPE, 2019–2032 (USD
MILLION) 47
TABLE 4 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, FOR DRUG ABUSE TREATMENT, BY TYPE, 2019–2032 (USD MILLION)
47
TABLE 5 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 50
TABLE 6 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION) 53
TABLE 7 GSK PLC: PRODUCTS OFFERED 59
TABLE 8 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 62
TABLE 9 WELLONA PHARMA: PRODUCTS OFFERED 65
TABLE 10 INTAS PHARMACEUTICALS LTD.: PRODUCTS OFFERED 67
TABLE 11 ROSEMONT PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 69
TABLE 12 MALLINCKRODT PLC: PRODUCTS OFFERED 72
TABLE 13 ADCOCK INGRAM: PRODUCTS OFFERED 75
TABLE 14 PFIZER INC.: PRODUCTS OFFERED 79
TABLE 15 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 83
TABLE 16 UMSEBE HEALTHCARE: PRODUCTS OFFERED 86
LIST OF FIGURES
FIGURE 1 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET: STRUCTURE 15
FIGURE 2 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET: MARKET GROWTH FACTOR ANALYSIS (2018-2032) 31
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 33
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032) 34
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET 36
FIGURE 6 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, TREATMENT TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD
MILLION) 45
FIGURE 7 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, BY TREATMENT TYPE, 2023 & 2032 (USD MILLION) 46
FIGURE 8 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET SHARE (%), BY TREATMENT TYPE, 2023 47
FIGURE 9 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2023 & 2032
(USD MILLION) 49
FIGURE 10 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2023 & 2032 (USD MILLION) 50
FIGURE 11 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2023 51
FIGURE 12 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, END USER SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
52
FIGURE 13 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET, BY END USER, 2023 & 2032 (USD MILLION) 53
FIGURE 14 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET SHARE (%), BY END USER, 2023 53
FIGURE 15 SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 55
FIGURE 16 COMPETITOR DASHBOARD: SOUTH AFRICA SUBSTANCE ABUSE TREATMENT MARKET 56
FIGURE 17 GSK PLC: FINANCIAL OVERVIEW SNAPSHOT 59
FIGURE 18 GSK PLC: SWOT ANALYSIS 60
FIGURE 19 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT 62
FIGURE 20 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 63
FIGURE 21 MALLINCKRODT PLC: FINANCIAL OVERVIEW SNAPSHOT 71
FIGURE 22 MALLINCKRODT PLC: SWOT ANALYSIS 73
FIGURE 23 ADCOCK INGRAM: FINANCIAL OVERVIEW SNAPSHOT 75
FIGURE 24 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 78
FIGURE 25 PFIZER INC.: SWOT ANALYSIS 79
FIGURE 26 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT 82
FIGURE 27 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 83
提及公司
Teva Pharmaceutical Industries Ltd.GSK PlcPfizer Inc.Sun Pharmaceutical Industries LtdMallinckrodt PLCAdcock Ingram.
同分類最新報告（醫療與生命科學）
查看醫療與生命科學全部報告 →
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們